The monoclonal antibody trastuzumab (Herceptin) may be effective against HER2-negative breast cancers in addition to HER2-positive disease, based on recent research findings. As recounted in a UM Health System statement accompanying the release of the study, new analyses of old data had revealed that women whose tumors were incorrectly categorized as HER2-positive benefited from adjuvant trastuzumab therapy. Read more here.
Study mentioned: Ithimakin S, et al. HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab. Cancer Res. 2013 Mar 1;73(5):1635-46. PMID: 23442322
No comments:
Post a Comment